You are here: Home: Audio Program Guide: CCU Surgeons 1 | 2008 Audio: CCU Surgeons 1 | 2008
Go to interview withSteven A Curley, MD Go to interview with Daniel G Haller, MD Go to interview with Nicholas J Petrelli, MD Go to interview with Richard M Goldberg, MD
To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.

 

Steven A Curley, MD Professor of Surgical Oncology Charles B Barker Chair in Surgery The University of Texas MD Anderson Cancer Center Houston, Texas
	Click here to download the entire interview
Track 1	Surgical resection of limited hepatic and/or pulmonary metastases with curative intent
Track 2	Conversion of unresectable metastases to resectable disease with neoadjuvant therapy
Track 3	Management of metastatic colorectal cancer and a synchronous asymptomatic primary tumor
Track 4	Timing of surgery and systemic therapy in the treatment of primary colorectal cancer and resectable synchronous hepatic metastases
Track 5	Simultaneous resection of a primary tumor and metastases
Track 6	Portal vein embolization prior to hepatic resection
Track 7	Surgical challenges associated with hepatic resection
Track 8	Impact of bevacizumab on wound healing
Track 9	Bowel perforation associated with bevacizumab
Track 10	Do extrahepatic metastases preclude hepatic resection of metastases?
Track 11	Hyperthermic chemotherapy perfusion for the treatment of peritoneal metastases
Track 12	Resection versus radiofrequency ablation (RFA) in clinical practice
Track 13	RFA: Clinical indications and side effects
Track 14	Paradigm shifts in the management of rectal cancer
Track 15	Tolerability of oxaliplatin-based adjuvant chemotherapy
Track 16	Effect of diet and exercise on rate of relapse

Daniel G Haller, MD Professor of Medicine Abramson Cancer Center at the University of Pennsylvania Philadelphia, Pennsylvania
	Click here to download the entire interview
Track 1	Imaging techniques used in the assessment of rectal cancer
Track 2	Treatment of low rectal lesions and sphincter preservation
Track 3	Neoadjuvant therapy versus up-front surgery for the treatment of high rectal lesions
Track 4	Clinical indications and timing of neoadjuvant therapy in the treatment of rectal cancer
Track 5	Local versus total mesorectal excision
Track 6	NSABP-R-04: Preoperative chemoradiation therapy with capecitabine versus 5-FU, with or without oxaliplatin, for rectal cancer
Track 7	Preoperative oxaliplatin-based chemoradiation therapy for the treatment of rectal cancer in clinical practice
Track 8	Combining radiation therapy and biologic therapy in the neoadjuvant setting
Track 9	Synergism of biologic agents with radiation therapy and/or chemotherapy
Track 10	Bevacizumab-associated side effects and complications

Nicholas J Petrelli, MD Bank of America Endowed Medical Director Helen F Graham Cancer Center at Christiana Care Professor of Surgery Thomas Jefferson University Newark, Delaware
	Click here to download the entire interview
Track 1	Phase III trial evaluating surgery with or without perioperative FOLFOX for patients with resectable hepatic metastases from colorectal cancer
Track 2	Hepatic toxicity secondary to neoadjuvant chemotherapy
Track 3	Biologic agents in the perioperative setting
Track 4	Conversion of inoperable liver metastases to resectable disease
Track 5	RFA versus hepatic resection
Track 6	Importance of hospital volume and surgeon experience in hepatic surgery
Track 7	Management of primary colon or rectal cancer with synchronous liver metastases
Track 8	NSABP-C-10: FOLFOX and bevacizumab for metastatic and synchronous asymptomatic primary colon cancer
Track 9	Cytoreductive surgery with intraperitoneal hyperthermic perfusion for peritoneal carcinomatosis
Track 10	Tolerability of cytoreductive surgery with intraperitoneal hyperthermic perfusion
Track 11	Variables affecting lymph node sampling
Track 12	Monitoring patients for recurrence after resection of primary colon or rectal cancer
Track 13	Future directions in the management of rectal cancer

Richard M Goldberg, MD Professor and Chief Division of Hematology/Oncology Associate Director University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
	Click here to download the entire interview
Track 1	Quality of life after adjuvant FOLFOX
Track 2	Impact of bevacizumab on quality of life
Track 3	Side effects of bevacizumab and cetuximab
Track 4	Risk of bowel perforation secondary to bevacizumab
Track 5	Correlation between diet and exercise and recurrence among patients with primary colorectal cancer
Track 6	Impact of aspirin, calcium and vitamin D on the rate of recurrence in colorectal cancer
Track 7	Surveillance of patients for the early detection of metastatic lesions with the intent to cure
Track 8	Clinical trial evaluating surgery with or without perioperative adjuvant therapy
Track 9	Qualifications of a hepatic surgeon
Track 10	Hepatic resection of metastases with the intent to cure
Track 11	Response of hepatic metastases to biologic therapies
Track 12	Phase II trial of FOLFOX and bevacizumab for metastatic and synchronous asymptomatic primary colon cancer
Track 13	Potential mechanism of action of bevacizumab
Track 14	Identifying subsets of colorectal cancer for treatment selection